Importance and barriers to hepatitis A immunization and the clinical relevance of inactivated hepatitis A vaccine (TZ84 strain): insights from the pediatric experts
DOI:
https://doi.org/10.18203/2349-3291.ijcp20262442Keywords:
Hepatitis A, Vaccination, Pediatricians, Focus group discussion, IndiaAbstract
The epidemiology of hepatitis A in India is shifting from high to intermediate endemicity, leading to a growing number of predisposed adolescents and adults who are at greater risk of symptomatic illness and sequelae. Vaccination is an efficacious preventative measure; yet, certain obstacles persist that hinder optimum vaccine use. This expert review aimed to explore the challenges associated with hepatitis A vaccination in India and to gather insights from pediatricians on the clinical relevance and factors influencing their choice of inactivated hepatitis A vaccines, with particular reference to the TZ84 strain. A focused group discussion (FGD) was conducted with 11 practicing pediatricians from various regions of India. The discussion examined opinions related to the epidemiological aspects of hepatitis A, immunization methodologies, obstacles to vaccine adoption, and determinants affecting vaccine choice. Pediatricians identified multiple challenges, such as financial obstacles, gaps in caregiver awareness, and a lack of hepatitis A vaccination in UIP. Participants highlighted the necessity for enhanced public health education and more robust policy initiatives aimed at increasing vaccination coverage. The inactivated hepatitis A vaccine (TZ84 strain) was considered clinically significant, given its demonstrated ability to elicit strong and durable immune responses and its potential for long-term protection against hepatitis A infection. The changing epidemiology of hepatitis A in India underscores the importance of strengthening vaccination strategies. Addressing policy, awareness, and accessibility barriers may improve vaccine uptake and reduce disease burden. Adoption of inactivated hepatitis A vaccines may help reduce disease burden, with TZ84 strain–based vaccine representing a reliable option for sustained protection.
References
Singh N, Naj Z, Sobit, Panwar G. Hepatitis A in India: a review of current knowledge and future perspectives. J Surv Fish Sci. 2023;10(3):269-74.
World Health Organization. Hepatitis A. 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a. Accessed on 15 March 2026.
Girish V, Grant LM, John S. Hepatitis A. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2026.
Grover M, Gupta E, Samal J, Prasad M, Prabhakar T, Chhabra R, et al. Rising trend of symptomatic infections due to Hepatitis A virus infection in adolescent and adult age group: an observational study from a tertiary care liver institute in India. Indian J Med Microbiol. 2024;50:100653.
Agrawal A, Singh S, Kolhapure S, Hoet B, Arankalle V, Mitra M. Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent. Infect Dis Ther. 2019;8(4):483-97.
Indian Academy of Pediatrics Advisory Committee on Vaccines and Immunization Practices. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2023) and Update on Immunization for Children Aged 0 Through 18 Years. Indian Pediatr. 2024;61(2):113-25.
Verma R, Khanna P. Hepatitis A vaccine should receive priority in National Immunization Schedule in India. Hum Vaccin Immunother. 2012;8(8):1132-4.
US Department of Health and Human Services. Types of vaccines. Washington, DC: HHS. Available at: https://www.hhs.gov/immunization/basics/types/ index.html. Accessed on 15 March 2026.
Zhang X, An J, Tu A, Liang X, Cui F, Zheng H, et al. Comparison of immune persistence among inactivated and live attenuated hepatitis A vaccines 2 years after a single dose. Hum Vaccin Immunother. 2016;12:2322-6.
Hussain Z, Shaikh I, Khan S, Sinh R, Patel K, Patel V. Insights of hepatitis A virus disease burden in Indian subcontinent: why urbanized localities are vulnerable to disease outbreaks? Explor Dig Dis. 2025;4:100593.
Rasheed A, Saeed S. Acute hepatitis a virus infection presenting with multiorgan dysfunction: a case report. Cases J. 2009;2:8124.
Das AK. Changing seroepidemiology of hepatitis A infection and its prevention in endemic regions. Int J Health Allied Sci 2016;5(2):75-80.
Arankalle V, Tiraki D, Kulkarni R, Palkar S, Malshe N, Lalwani S, et al. Age stratified anti-HAV positivity in Pune, India after two decades: Has voluntary vaccination impacted overall exposure to HAV? J Viral Hepat. 2019;26(6):757-60.
Mathur P, Arora NK. Epidemiological transition of hepatitis A in India: issues for vaccination in developing countries. Indian J Med Res. 2008;128(6):699-704.
Matheny SC, Kingery JE. Hepatitis A. Am Fam Physician. 2012;86(11):1027-34.
WHO position paper on hepatitis A vaccines – June 2012. Weekly Epidemiological Record. 2012;28-29:261-76.
Lalwani S, Palkar S, Kaur G, Mitra M, Deshmukh R, Kulkarni R, et al. Age-stratified prevalence of anti-hepatitis A virus antibodies in four metropolitan Indian cities and recent changes in Pune city. Indian J Gastroenterol. 2025;45(4):735-44.
Shah N, Faridi MMA, Bhave S, Ghosh A, Balasubramanian S, Arankalle V, et al. Expert consensus and recommendations on the live attenuated hepatitis A vaccine and immunization practices in India. Hum Vaccin Immunother. 2025;21(1):2447643.
Trivedi C, Marathe S, Bhat N, Karadkhele A, Puppalwar G, Jain R. Clinician's Perspective on the Use of Hepatitis A Vaccine in Indian Children. Pediatr Infect Dis. 2018;1(4):148-53.
Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence. Hum Vaccin Immunother. 2021;17(5):1496-519.
Shanmugam V, Ward J, Vijayakumar S, Khwairakpam G, James C, Shanmugam L, et al. Challenges and opportunities in combating viral hepatitis in India: insights from the Indian Hepatitis Summit 2025. BMC Proc. 2026;20(Suppl 4):4.
Rao S, Mao JS, Motlekar S, Fangcheng Z, Kadhe G. A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children. Hum Vaccin Immunother. 2016;12(12):3160-5.
Wang Y, Qi Y, Xu W, Hu Y, Wang L, Yu Y, et al. Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction. Hum Vaccin Immunother. 2020;16(10):2559-64.
Yu YP, Chen JT, Jiang ZW, Wang L, Yu CK, Yan XY, et al. Modeling the Long-term Antibody Response and Duration of Immune Protection Induced by an Inactivated, Preservative-free Hepatitis A Vaccine (Healive) in Children. Biomed Environ Sci. 2020;33(7):484-92.
Shouval D. Immunization against hepatitis A. Cold Spring Harb Perspect Med. 2019;9(2):a031682.
Wu JY, Liu Y, Chen JT, Xia M, Zhang XM. Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine healive®. Hum Vaccin Immunother. 2012;8:1836-4.
Yewale V, Marathe S. Inactivated TZ84 strain hepatitis A vaccine and its impact: A narrative review. Indian J Child Health. 2024;10(12):1059-64.
Kasi SG, Prabhu SV, Sanjay S, Chitkara A, Mitra M. Prefilled syringes versus vials: impact on vaccination efficiency and patient safety in Indian private market. Pediatr Infect Dis. 2013;5(4):181-6.
Thuluva S, Matur R, Tsa K, Gv SR. A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEVTM) in 1-15 years-old healthy hepatitis A vaccine-naïve children. Vaccine. 2021;39:7166-74.
Abarca K, Ibánez I, Perret C, Vial P, Zinsou JA. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children. Int J Infect Dis. 2008;12(3):270-7.
World Health Organization. Hepatitis A vaccines: WHO position paper – October 2022. Wkly Epidemiol Rec. 2022;97(40):493-512.
Downloads
Published
How to Cite
Issue
Section
